4th Category 1 Focus Group Meeting

Why attend?

Category 1 Testing is a relatively new discipline to assess the performance of abuse deterrent opioid formulations (ADF) with laboratory experiments. The FDA has issued Category 1 guidelines for branded and generic products in the past years. However, ADF technologies, regulatory expectations, and real world abuse techniques are evolving very rapidly and staying up-to-date is more important than ever before. 

Register now and take this unique opportunity to…

  • … learn about recent trends and regulatory expectations for Category 1 Testing 
  • ... see how to obtain relevant data for all stages of drug development - from initial formulation screening to regulatory submission and Advisory Committee.  
  • … find out how ADFs are evolving into areas beyond classical opioids. 
  • … meet and network with stakeholders from FDA, industry, Academia, consultants, CROs and CDMOs. 

This is a must-attend meeting for everyone involved in the development, manufacture, testing, and commercialization of abuse deterrent products.  

We are looking forward to meeting you in June.

Venue & Accommodations



June 4-5, 2019



Embassy Suites by Hilton Alexandria Old Town

1900 Diagonal Road

Alexandria, Virginia 




The hotel is across the street from the King Street metro station, providing easy access to Washington, DC.

10 min. from Washington National Airport

35 min. from Dulles International Airport

Day 1 – June 4th, 2019

Day 2 – June 5th, 2019